Amgen Inc. Share Price and Company Fundamentals



Price
$248.35
Change
-3.740 (-1.484%)
52 week
198.64 - 258.45

Last traded: Today at 8:00 PM

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Key Metrics

PE ratio

21.44

PB ratio

55.75

Dividend yield

2.94%

Beta

0.56

Market cap

-

Enterprise value

-

Company profile

Industry / SectorDrug Manufacturers—General / Healthcare
Full time employees24200
Websitehttps://www.amgen.com
Mailing addressOne Amgen Center Drive Thousand Oaks CA 91320-1799 United States
Phone / Fax805 447 1000 / 805 447 1010

Dividends

Dividend yield

2.94%

Dividend amount

$7.40

Payout ratio

62.93%

5Y Avg. yield

2.79%

Amgen Inc. paid $7.40 dividend and the ex-dividend date was 16 Aug 2022.The dividend payout ratio is 62.93%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.AMGN dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.

AMGN's forward dividend amount is $7.76 and the forward dividend yield is 3.12%. A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.

Company Executives

As of Aug 2022, following are the company executives and directors listed on Amgen Inc..

NameTitleAgeTotal Pay
Mr. Robert A. BradwayChairman, CEO & Pres585.81M
Mr. Peter H. GriffithExec. VP & CFO622.66M
Mr. Esteban SantosExec. VP of Operations532.61M
Dr. David M. Reese M.D.Exec. VP of R&D582.79M
Mr. Murdo GordonExec. VP of Global Commercial Operations542.82M
Ms. Linda H. LouieVP of Fin. & Chief Accounting Officer
Mr. Mike ZahigianSr. VP & Chief Information Officer
Mr. Arvind SoodVP of Investor Relations
Mr. Jonathan P. GrahamExec. VP, Gen. Counsel & Sec.60
Ms. Nancy A. GrygielSr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer53

Profitability and management effectiveness

Profit margin

24.92%

Operating margin

37.75%

Return on assets

10.46%

Return on equity

123.31%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Amgen Inc. is and its enterprise value is .

The AMGN's stocks Beta value is 0.56 making it 44% less volatile compared to NASDAQ market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Amgen Inc. (NASDAQ:AMGN) Frequently Asked Questions

1. What is Amgen Inc.'s Stock Symbol?

Amgen Inc. trades on NASDAQ under the ticker symbol "AMGN".

2. What is Amgen Inc.'s stock price today?

One share of AMGN stock can currently be purchased for approximately $248.35.

3. How can I contact Amgen Inc.?

Amgen Inc.'s mailing address is One Amgen Center Drive Thousand Oaks CA 91320-1799 United States. The company can be reached via phone at 805 447 1000.

4. What is Amgen Inc.'s official website?

The official website of Amgen Inc. is https://www.amgen.com.